文献速递临床试验与 GCP基础与转化研究

抗α4β7单克隆抗体维得利珠单抗用于HIV感染者的开放标签1期临床试验

An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals.
PubMed 文献 · Sci Transl Med · 2019-09-05

在20名HIV感染者中开展维得利珠单抗开放标签1期临床试验,药物输注耐受良好,无与研究药物相关的严重不良事件。中断抗逆转录病毒治疗后,达到方案重启治疗标准的中位时间为13周,血浆病毒载量<400拷贝/ml的中位持续时间为5.4周,仅1例受试者出现 prolonged 病毒抑制。结果提示阻断α4β7可能不是诱导HIV感染者ART中断后病毒学缓解的有效策略。

要点

  • 维得利珠单抗在20名HIV感染者中输注耐受良好,无研究药物相关严重不良事件。
  • 中断ART后达到方案重启治疗标准的中位时间为13周,血浆病毒载量<400拷贝/ml的中位持续时间为5.4周。
  • 仅1例受试者在中断ART后出现 prolonged 血浆病毒抑制,提示阻断α4β7可能不是诱导病毒学缓解的有效策略。

核心结论

  • 阻断α4β7可能不是诱导HIV感染者中断ART后病毒学缓解的有效策略。

研究设计与样本

  • 开放标签1期临床试验,纳入20名HIV感染者,给予抗α4β7单克隆抗体维得利珠单抗输注,随后中断ART。

主要发现

  • 维得利珠单抗输注耐受良好,无与研究药物相关的严重不良事件。
  • 中断ART后,达到方案重启治疗标准的中位时间为13周。
  • 中断ART后,血浆病毒载量<400拷贝/ml的中位持续时间为5.4周。
  • 仅1例受试者在中断ART后出现 prolonged 血浆病毒抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the substantial clinical benefits of antiretroviral therapy (ART), complete eradication of HIV has not been possible. The gastrointestinal tract and associated lymphoid tissues may play an important role in the pathogenesis of HIV infection. The integrin α4β7 facilitates homing of T lymphocytes to the gut by binding to the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on venules in gut-associated lymphoid tissue. CD4+ T cells with increased expression of α4β7 are susceptible to HIV infection and may be key players in subsequent virus dissemination. Data from nonhuman primate models infected with simian immunodeficiency virus (SIV) have suggested that blockade of the α4β7/MAdCAM-1 interaction may be effective at preventing SIV infection and may have beneficial effects in animals with established viral infection. To explore whether these findings could be reproduced in HIV-infected individuals after interruption of ART, we conducted an open-label phase 1 clinical trial of vedolizumab, a monoclonal antibody against α4β7 integrin. Vedolizumab infusions in 20 HIV-infected individuals were well tolerated with no serious adverse events related to the study drug. After interruption of ART, the median time to meeting protocol criteria to restart therapy was 13 weeks. The median duration of plasma viremia of <400 copies/ml was 5.4 weeks. Only a single subject in the trial experienced prolonged suppression of plasma viremia after interruption of ART. These results suggest that blockade of α4β7 may not be an effective strategy for inducing virological remission in HIV-infected individuals after ART interruption.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Sneller MC, Clarridge KE, Seamon C, et al. An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals. Sci Transl Med. 2019. PMID: 31488581. doi:10.1126/scitranslmed.aax3447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。